Researchers tracked over 10,000 patients and found the risk of self-harm was highest before starting gabapentinoids and again shortly after stopping, highlighting key periods for clinical monitoring.
Higher genetic risk for schizophrenia correlated with reduced macular thickness, but the “variation is very unlikely to have an impact on visual acuity.”
The FDA has authorized Minder, the first implantable continuous electroencephalogram monitor, offering long-term brain activity tracking for improved epilepsy management, available in the U.S.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
"Readers should not have to infer what was probably done; they should be told explicitly." This principle drives the comprehensive CONSORT 2025 update, with its 7 new checklist items aimed at improving clinical trial transparency.